Anti-T2R30/ TAS2R30/ T2R47 monoclonal antibody

Anti-T2R30/ TAS2R30/ T2R47 antibody for FACS & in-vivo assay

Target products collectionGo to TAS2R30/TAS2R30 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1765-Ab-1/ GM-Tg-hg-MP1765-Ab-2Anti-Human TAS2R30 monoclonal antibodyHuman
GM-Tg-rg-MP1765-Ab-1/ GM-Tg-rg-MP1765-Ab-2Anti-Rat TAS2R30 monoclonal antibodyRat
GM-Tg-mg-MP1765-Ab-1/ GM-Tg-mg-MP1765-Ab-2Anti-Mouse TAS2R30 monoclonal antibodyMouse
GM-Tg-cynog-MP1765-Ab-1/ GM-Tg-cynog-MP1765-Ab-2Anti-Cynomolgus/ Rhesus macaque TAS2R30 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1765-Ab-1/ GM-Tg-felg-MP1765-Ab-2Anti-Feline TAS2R30 monoclonal antibodyFeline
GM-Tg-cang-MP1765-Ab-1/ GM-Tg-cang-MP1765-Ab-2Anti-Canine TAS2R30 monoclonal antibodyCanine
GM-Tg-bovg-MP1765-Ab-1/ GM-Tg-bovg-MP1765-Ab-2Anti-Bovine TAS2R30 monoclonal antibodyBovine
GM-Tg-equg-MP1765-Ab-1/ GM-Tg-equg-MP1765-Ab-2Anti-Equine TAS2R30 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1765-Ab-1/ GM-Tg-hg-MP1765-Ab-2; GM-Tg-rg-MP1765-Ab-1/ GM-Tg-rg-MP1765-Ab-2;
GM-Tg-mg-MP1765-Ab-1/ GM-Tg-mg-MP1765-Ab-2; GM-Tg-cynog-MP1765-Ab-1/ GM-Tg-cynog-MP1765-Ab-2;
GM-Tg-felg-MP1765-Ab-1/ GM-Tg-felg-MP1765-Ab-2; GM-Tg-cang-MP1765-Ab-1/ GM-Tg-cang-MP1765-Ab-2;
GM-Tg-bovg-MP1765-Ab-1/ GM-Tg-bovg-MP1765-Ab-2; GM-Tg-equg-MP1765-Ab-1/ GM-Tg-equg-MP1765-Ab-2
Products NameAnti-TAS2R30 monoclonal antibody
Formatmab
Target NameTAS2R30
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TAS2R30 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species T2R30/ TAS2R30/ T2R47 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1765
    Target NameTAS2R30
    Gene ID259293
    Gene Symbol and SynonymsT2R30,T2R47,TAS2R30,TAS2R47
    Uniprot AccessionP59541
    Uniprot Entry NameT2R30_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000256188
    Target ClassificationGPCR

    The target: TAS2R30, gene name: TAS2R30, also named as T2R30, T2R47, TAS2R47. Enables bitter taste receptor activity. Involved in detection of chemical stimulus involved in sensory perception of bitter taste. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.